Orakl Oncology

Orakl Oncology is a Paris-based techbio company building a first-in-class, AI-native predictive platform to disrupt cancer drug development. The company's core technology involves creating 'Patient Tumor Avatars' from patient-derived organoids and multimodal data, which are used by a proprietary AI engine to predict clinical trial outcomes and identify novel drug targets. Spun out of Gustave Roussy, the company partners with hospitals to build its avatar collection and with pharmaceutical companies to de-risk their R&D pipelines, having raised €11M in seed funding from European investors.

AI-native predictive platform integrating patient-derived organoids (Patient Tumor Avatars) with multimodal genomic, transcriptomic, and clinical data. Uses a proprietary AI engine for zero-shot prediction of clinical trial outcomes and novel target identification.

Orakl competes in the crowded AI-for-drug-discovery sector against pure-play AI firms (e.g., Exscientia, Recursion), large biopharma internal efforts, and other organoid/avatar companies. Its key differentiator is the closed-loop integration of a proprietary, multimodal patient-derived avatar biobank with a clinical-outcome-focused AI engine.